The Case For Synthetic DNA In Modern Therapeutic Development

The race to accelerate therapeutic development is forcing the industry to rethink one of its most fundamental starting materials: DNA. In this conversation, Kate Broderick explores how synthetic DNA is reshaping drug and vaccine manufacturing by eliminating the need for bacterial fermentation, reducing impurities, and dramatically shortening development timelines.

What once took months can now be accomplished in weeks, creating new opportunities for RNA therapeutics, cell and gene therapies, infectious disease responses, and personalized cancer treatments. As regulatory acceptance grows and pressure mounts to deliver treatments faster, developers face an important question: is reliance on traditional plasmid DNA limiting innovation

Discover why synthetic DNA is emerging as a practical path to faster, more agile therapeutic development and how it could help bring life-changing medicines to patients sooner.